| Literature DB >> 28190261 |
Qing-Hai Meng1, Harry N White2.
Abstract
CD21int CD23+ IgM+ mouse follicular B cells comprise the bulk of the mature B-cell compartment, but it is not known whether these cells contribute to the humoral antibody response. We show using a direct RT-PCR method for antigen-specific VH, that FACS-sorted mouse CD21int CD23+ B cells express specific secretory IgM VH transcripts in response to immunization and also exhibit a memory response. The secretory IgM expressed is distinct from the IgG expressed by cells of this phenotype, which we also analyse here, having a distinct broader distribution of CDR-H3 sequences and zero or low levels of somatic mutation in the region analysed. These results imply that cells of the CD21int CD23+ phenotype have distinct IgM+ and IgG+ populations that contribute directly to the humoral antibody and memory responses by expressing antigen-specific secretory immunoglobulin. We also argue that the more diverse CDR-H3 sequences expressed by antigen-experienced IgM+ CD21int CD23+ follicular B cells would place them at the bottom of a recently hypothesized memory B-cell hierarchy.Entities:
Keywords: B cells; follicular; memory; repertoire
Mesh:
Substances:
Year: 2017 PMID: 28190261 PMCID: PMC5418461 DOI: 10.1111/imm.12724
Source DB: PubMed Journal: Immunology ISSN: 0019-2805 Impact factor: 7.397
Figure 1FACS gating and workflow for RT‐PCR analysis of specific antibody expression. Cell suspensions were sorted for CD19+ CD21int CD23+ cells when appropriate. Upper left hand panel shows a typical sort and the follicular cell gate used. Upper right hand panel shows a re‐sort of CD21int CD23+ cells after sample sort was completed.
Figure 2The VHOx‐1 secretory IgM response to phenyl‐oxazolone (phOx) at the whole spleen level. VHOx‐1 secretory IgM RT‐PCR of whole spleen cell suspension cDNA. Cells from single mouse spleen per sample track. Three samples per group from one representative experiment. Control, unimmunized; day 4: Four days after immunization with phOx‐CSA/adjuvant; day 11: 11 days after immunization with phOx‐CSA/adjuvant; day 50: 50 days after immunization with phOx‐CSA/adjuvant; ox prime/ox boost: re‐immunized with soluble phOx‐CSA 50 days after priming with phOx‐CSA/adjuvant, samples collected 4 days later; carrier‐prime/ox boost: re‐immunized with soluble phOx‐CSA 50 days after priming with CSA/adjuvant, samples collected 4 days later. The C6 band, containing phOx‐specific transcripts with six amino‐acid CDR‐H3s, is indicated with an arrow. Numerical data derived as described ref. 14 C6 level %, the level of C6 transcripts in that sample as a percentage of the levels of all other VHOx‐1 transcript lengths. DXG/seq, the number of sequences in that C6 band containing the DXG motif out of all sequences from that band. Mean C6 level, the mean level of C6 transcripts in that group. DXG, the mean level of DXG motif containing C6 transcripts in that group as a percentage of all other VHOx‐1. To calculate this mean value, the individual sample DXG values were calculated first, using individual C6% × DXG/Seq values, and then averaged; Non DXG, the mean level of C6 transcripts without the DXG motif expressed as a percentage of all other VHOx‐1. Lower panel shows individual C6 levels plotted (dots) and the mean for each group (solid bar), and panels correspond to those above.
Frequency of, and mutation in, the DXG motif transcripts up‐regulated in response to phenyl‐oxazolone
| Prime day 11 | Boost | |||
|---|---|---|---|---|
| % DXG | % mutation in DXG | % DXG | % mutation in DXG | |
| Whole spleen | ||||
| Secretory IgM | 25·3 | 0·0 (0/7) | 94·1 | 0·35 (15/37) |
| CD21int CD23+ cells | ||||
| Secretory IgM | 4·2 | 0·0 (0/2) | 63·6 | 0·28 (7/21) |
| Membrane IgM | 64·2 | 0·32 (11/29) | 59·3 | 0·39 (6/13) |
| Secretory IgG | 100·0 (34/34) | 0·2 (9/34) | 100·0 (30/30) | 1·25 (44/30) |
| Membrane IgG | 95·2 (20/21) | 0·47 (11/20) | 100·0 (40/40) | 1·38 (65/40) |
Estimated frequency in % of the DXG motif in transcripts expressed above pre‐immune levels; and level of somatic mutation in the FR3 region of the VHOx‐1/DXG sequences. Day 11: 11 days after immunization with phOx‐CSA/adjuvant, boost: re‐immunized with soluble phOx‐CSA 50 days after priming with CSA/adjuvant, samples collected 4 days later. % DXG: Proportion of phenyl‐oxazolone (phOx) ‐induced transcripts that contain DXG motif. For estimating % DXG in phOx‐induced transcripts, IgM values were calculated from data in Figs 2 and 3, except membrane IgM data which is derived from ref. 13 by subtracting the mean pre‐immune values of DXG and non‐DXG transcript levels from the respective mean values for each experimental group and then calculating what percentage were DXG/non‐DXG. For each experimental group, between 42 and 57 DNA sequences were analysed in total for DXG from the three independent samples shown in these figures. VHOx‐1/C6 IgG is not readily detectable in pre‐immune samples so all is assumed phOx‐induced. Figures in brackets by IgG values show DXG/number of total sequences analysed, a pool from the three independent samples in each group.
% mutation in DXG: Figures show % somatic mutation in the FR3 region of VHOx‐1/C6 for all transcripts in group with DXG motif. Figures in brackets show number of mutations/number of sequenced 117 bp FR3 regions.
Figure 3The VHOx‐1 secretory IgM response to phenyl‐oxazolone (phOx) in the CD21int CD23+ population. VHOx‐1 secretory IgM RT‐PCR of sorted CD21int CD23+ cell cDNA. Cells were from single mouse per sample track, three samples per group. For statistical calculations a further three samples from an independent experiment for control and day 11 post‐immunization samples were obtained for data in lower panel. The extra C6%‐level data‐points not shown in upper panel, from the second experiment were: Control: 9·0, 4·3, 9·6; day 11: 15·8, 20·5, 18·2. Sample time‐points, derivation of numerical data and annotation as described in Fig. 2. Lower panel: shows individual C6 levels plotted (dots), the mean for each group (solid bar) which may differ from upper panel because of the inclusion of extra samples, and the 95% confidence intervals for the mean, calculated according to ref. 33; for n = 3 or 6 the 95% CI = 4 × SEM. Confidence intervals not shown for day 4 samples because only one individual showed response.